<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(3)</volume><submitter>Matsuoka T</submitter><journal>Translational cancer research</journal><pagination>1507-1510</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11985196</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.</pubmed_title><pmcid>PMC11985196</pmcid><pubmed_authors>Yamamoto Y</pubmed_authors><pubmed_authors>Matsuoka T</pubmed_authors><pubmed_authors>Yashiro M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.</name><description/><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-06-01T08:55:42.695Z</modification><creation>2025-07-10T03:08:05.082Z</creation></dates><accession>S-EPMC11985196</accession><cross_references><pubmed>40224980</pubmed><doi>10.21037/tcr-2024-2421</doi></cross_references></HashMap>